Test Price
1,700 AED✅ Home Collection Available
Breast Biopsy (Modified Radical Mastectomy) with ER, PR, HER2/neu, Ki‑67 Panel in UAE | 1,700 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Executive Summary
- 99.9% Diagnostic Sensitivity via ISO‑accredited IHC with digital pathology quantification and double‑blind histopathological interpretation.
- Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Secure Medical Courier Solid Tissue Specimen Retrieval – temperature‑controlled chain of custody for archival FFPE blocks and slides.
- Insurance Direct Billing – WhatsApp +971 54 548 8731 for eligibility verification and pre‑authorisation.
Test Overview & Methodology
This advanced tissue‑based panel is the gold standard for breast cancer subtyping following a modified radical mastectomy. It simultaneously quantifies oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), and the proliferation marker Ki‑67, enabling precise oncologic decision‑making and eligibility for targeted therapies.
Immunohistochemistry (IHC) is performed on formalin‑fixed paraffin‑embedded tissue sections using validated monoclonal antibodies. Digital image analysis scoring (Allred for ER/PR, ASCO/CAP for HER2, and percentage index for Ki‑67) ensures objective, reproducible results.
| Feature | Our Test (DHA/ISO) | Routine Biopsy |
|---|---|---|
| Methodology | IHC + Digital Pathology | H&E Only |
| Precision | 99.9% Sensitivity | Variable |
| Turnaround | 6 Days (Courier Retrieval) | 7–14 Days |
| Therapeutic Guidance | Full receptor & Ki‑67 profile | None |
Physician Insight & Safety Protocols
“A comprehensive immunohistochemical panel incorporating ER, PR, HER2/neu, and Ki‑67 provides the molecular blueprint essential for precision oncology following mastectomy. The Ki‑67 proliferation index stratifies luminal tumours and directly influences adjuvant chemotherapy decisions. Correlation with histologic grade, nodal status, and radiological staging remains imperative for optimal therapeutic planning.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
⚠ Medication Advisory
Never alter or discontinue any prescribed oncologic therapy—including tamoxifen, aromatase inhibitors, or trastuzumab—based solely on receptor results. All treatment modifications must be overseen by your treating oncologist in conjunction with full clinical and radiographic assessment.
Exclusion Criteria & Emergency Red Flags
- Active infection or open wound at the biopsy or surgical site.
- Uncorrected severe coagulopathy (INR > 2.0, platelets < 50,000/μL).
- Pregnancy – tissue sampling deferred unless maternal oncologic urgency outweighs fetal risk.
- Red Flags post‑procedure: excessive bleeding, rapidly expanding haematoma, fever > 38°C, or purulent discharge – seek immediate emergency care.
- Patient refusal or inability to provide informed consent; specimen integrity compromised by prolonged ischaemia (> 30 minutes before formalin fixation).
Patient FAQ & Clinical Guidance
1. What does the ER, PR, HER2/neu, Ki‑67 panel detect?
This test precisely evaluates oestrogen, progesterone, HER2/neu, and Ki‑67 receptor status on biopsied breast cancer tissue.
The panel uses immunohistochemistry on formalin‑fixed paraffin‑embedded sections to stain for hormone receptors and HER2 overexpression, while Ki‑67 is scored as a percentage of proliferating tumour cells. Results classify your cancer into luminal A, luminal B, HER2‑enriched, or basal‑like subtypes — directly influencing hormonal therapy, Herceptin eligibility, and chemotherapy decisions.
2. Why is Ki‑67 reported alongside hormone receptors?
Ki‑67 proliferation index differentiates indolent luminal A cancers from aggressive luminal B, altering chemotherapy recommendations.
Without Ki‑67, ER+/PR+ tumours may be misclassified as low risk. A high Ki‑67 (>20%) in a hormone‑receptor positive case often triggers adjunctive chemotherapy even when HER2 is negative. Thus the quadruple assay prevents undertreatment and overtreatment simultaneously.
3. Can this test be performed before mastectomy?
Core needle biopsy tissue can be used for the receptor panel, but a formal mastectomy specimen provides maximal tissue representation and accuracy.
Pre‑surgical biopsies allow neoadjuvant therapy planning. However, when complete mastectomy tissue is available, our test reduces sampling error and provides definitive receptor staining across the whole tumour. Your surgical oncologist will decide the optimal specimen type.
4. Will this test determine my exact treatment plan?
The panel provides critical predictive and prognostic information but is one component of a multidisciplinary assessment.
Your oncologist integrates these results with tumour grade, lymph node involvement, tumour size, genomic assays, and imaging to formulate a personalised treatment plan. Always discuss all findings with your healthcare team before making any therapeutic decisions.
UAE Regulatory & Data Privacy Adherence
Regulatory & Data Protection Framework
All clinical procedures and data handling comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is DHA‑licensed (Facility #1143) and ISO 9001:2015 certified. Specimen handling and reporting are conducted exclusively by DHA‑registered personnel under stringent confidentiality and security controls.
Clinical & Logistical Metadata
| Test Name | Breast Biopsy (Modified Radical Mastectomy) with ER, PR, HER2/neu, Ki‑67 Panel |
| Price (AED) | 1,700 AED |
| Turnaround Time | 6 Days (Secure Medical Courier Retrieval inclusive) |
| Sample Type / Matrix | Archival Surgical Tissue (FFPE Block / Slides from Modified Radical Mastectomy) |
| Methodology Used | Immunohistochemistry (IHC) with Digital Pathology Quantification (Allred / ASCO-CAP / Ki‑67 Index) |
| ICD-10-CM Code | C50.9 |
| LOINC Code | 85319-2 |
| DHA Facility License & Laboratory Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians